Paris, April 26, 2017 – 8.45 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, notably in oncology, announces that today’s Ordinary Shareholders’ General Meeting approved all resolutions submitted to their vote, with over 90% of favorable votes. Given that the quorum was not obtained for the Extraordinary General Meeting, shareholders are given notice of a further EGM on May 24th, 2017 at 3pm.
Shareholders approved the appointment of two new independent directors
Mrs. Christine Garnier (ESCP Europe) is co-founder and a Managing Partner of AEC Partners since 1998. Her consulting activity specializes in corporate, international and operational strategies across the life sciences industry. Over the last 20 years, Christine Garnier has managed more than 200 assignments on primary and specialty care products, vaccine products, as well as medical devices and OTC products. Before co-founding AEC Partners, Christine Garnier spent 12 years working in the pharmaceutical industry, holding marketing positions at Wyeth and international marketing and strategic planning positions at Rhône Poulenc Rorer.
Mrs. Elvira Sanz Urgoiti (Doctor in Pharmacy from the Complutense University of Madrid) has over 25 years of experience in the pharmaceutical industry, starting out as a research scientist before occupying positions of growing responsibility across various business areas for MSD, Roche and Cyanamid. In 2000, she was appointed CEO of Wyeth Pharma in Spain, before joining Wyeth’s US headquarters to develop a global project, reporting to the CEO of the group, for the restructuration of Wyeth’s affiliates at global level. In 2009, following Wyeth’s acquisition by Pfizer, she became Chairman and CEO of Pfizer Spain, a position she held until 2015.
These nominations follow the departures of Mr. David Solomon and Mr. Russell Greig.
Joe Zakrzewski, Chairman of Onxeo’s Board of Directors, says: “First, I would like to thank David and Russell for their commitment and strong contribution throughout their terms of office. The appointments of Christine Garnier and Elvira Sanz strengthen the Board’s expertise with highly-proficient profiles in pivotal areas for the Company: strategy, internationalization and the expectations of large pharmaceutical partners. We are delighted to welcome them to a Board that is so diverse, experienced and involved in Onxeo’s development.”
Renewal of Board appointments
The Annual General Meeting renewed the terms of office of Mrs Judith Greciet, Onxeo’s CEO and the company’s main shareholder, Financière de la Montagne, represented by Mr Nicolas Trebouta.
The Company’s governance has thus been renewed and supplemented with new areas of expertise, with a Board of Directors that has 9 members, including 7 independent Directors. It includes over 40% of women, in accordance with the French law of January 27, 2011 pertaining to gender parity on the Boards of Directors of listed companies.
Notice of new Extraordinary General Meeting on May 24, 2017
The final quorum of 24.205% was insufficient to enable the EGM resolutions to be voted. The company’s shareholders are therefore invited to attend an EGM, on second notice with the same agenda, on May 24th, 2017 at 3 pm at Onxeo’s headquarters (49, Boulevard du Général Martial Valin, 75015 Paris).